Molecularly targeted therapies for melanoma

International Journal of Dermatology

Volumn 52, Issue 5, 2013, Pages 523-530

  Liu, Lucinda S ^a   Colegio, Oscar R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; GLUTAMIC ACID; IMATINIB; IPILIMUMAB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; TRAMETINIB; VALINE; VASCULOTROPIN RECEPTOR; VEMURAFENIB;

ALOPECIA; AMINO ACID SUBSTITUTION; ARTHRALGIA; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLONAL ANERGY; DEPIGMENTATION; DERMATITIS; DIAPHORESIS; DRUG EFFICACY; DRUG MECHANISM; EDEMA; ENZYME INHIBITION; ERYTHEMA; EXON; FATIGUE; GENE MUTATION; HUMAN; HYPOPIGMENTATION; MELANOMA; MOLECULARLY TARGETED THERAPY; ONCOGENE; ONCOGENE C KIT; OVERALL SURVIVAL; PETECHIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY DISORDER; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PRURITUS; RASH; REVIEW; SIDE EFFECT; SKIN CARCINOMA; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; VITILIGO;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZAMIDES; HUMANS; IMMUNOTHERAPY; INDOLES; MELANOMA; MESYLATES; MOLECULAR TARGETED THERAPY; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84876433392     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2012.05829.x     Document Type: Review

References (43)

1. Poole CM, Guerry D. Melanoma: Prevention, Detection, and Treatment, 2nd edn. New Haven, CT: Yale University Press, 2005.
2. Roguin A. Rene Theophile Hyacinthe Laennec (1781-1826): the man behind the stethoscope. Clin Med Res 2006; 4: 230-235.
3. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
4. Heinz VL, ed. Progress in Skin Cancer Research. New York: Nova Science Publishers, 2007.
5. Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011; 16: 5-24.
6. Coit DG, Andtbacka R, Bichakjian CK, et al. Melanoma. J Natl Compr Canc Netw 2009; 7: 250-275.
7. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147.
8. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-4346.
9. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
10. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008; 105: 3041-3046.
11. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
12. Chabner BA. Early accelerated approval for highly targeted cancer drugs. N Engl J Med 2011; 364: 1087-1089.
13. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
14. Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N Engl J Med 2011; 365: 2439-2441.
15. Williams VL, Cohen PR, Stewart DJ. Sorafenib-induced premalignant and malignant skin lesions. Int J Dermatol 2011; 50: 396-402.
16. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009; 27: e59-e61.
17. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366: 207-215.
18. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140: 209-221.
19. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-435.
20. Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464: 427-430.
21. Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30: 316-321.
22. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468: 973-977.
23. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468: 968-972.
24. Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480: 387-390.
25. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
26. Tuma RS. Getting around PLX4032: studies turn up unusual mechanisms of resistance to melanoma drug. J Natl Cancer Inst 2011; 103: 170-177.
27. Ronnstrand L. Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci 2004; 61: 2535-2548.
28. Willmore-Payne C, Holden JA, Hirschowitz S, et al. BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol 2006; 37: 520-527.
29. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008; 14: 6821-6828.
30. Alexeev V, Yoon K. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 2006; 126: 1102-1110.
31. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305: 2327-2334.
32. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29: 2904-2909.
33. Cho JH, Kim KM, Kwon M, et al. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 2012; 30: 2008-2014.
34. Salama AK, Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2011; 17: 4622-4628.
35. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
36. Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. N Engl J Med 2011; 365: 1747-1748.
37. Burke MM, Kluger HM, Golden M, et al. Case report: response to ipilimumab in a patient with HIV with metastatic melanoma. J Clin Oncol 2011; 29: e792-e794.
38. Prieto PA, Yang JC, Sherry RM, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18: 2039-2047.
39. Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70: 5213-5219.
40. Litt's D.E.R.M Database. Informa Healthcare, 2012. http://www.drugeruptiondata.com/ [Accessed Feb 18, 2012].
41. Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther 2011; 24: 386-395.
42. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002; 346: 683-693.
43. Colegio OR, Leffell JD. Genetics of skin cancer. In: Rigel DSKJ, Ross M, Lim HW, et al., eds. Cancer of the Skin, 2nd edn. Philadelphia: Elsevier Saunders, 2011: 12-22.